Peter Attia MD327 - Choices, costs, and challenges in US healthcare: insurance, drug pricing, & potential reforms
CHAPTERS
- 0:00 – 13:11
Scale of US Healthcare Spending and Who Pays
After Peter Attia frames the discussion as a master class, Saum Sutaria sizes the US system at roughly $4 trillion, close to 20% of GDP. He breaks down who pays: consumers, employers, and federal and state government, and notes the 1954 tax advantage for employer-sponsored insurance.
- •Healthcare is about 17–18% of a roughly $28 trillion economy, or $11–12K per person
- •Funding is split roughly a quarter consumers, a quarter employers, and half government
- •Employer-sponsored insurance is unique to the US and rooted in the 1954 pre-tax benefit
- •Large employers often self-insure and use insurers only for administration
- •Federal healthcare spending (about $1.8–2T) is compared with defense and Social Security
- 13:11 – 16:39
Where the Money Goes: Administration and the Thirds
Sutaria explains how the money flows into private insurance, Medicare and Medicaid, and then to providers. He describes administration at 10–15% of spending and the rest split roughly into thirds across hospitals, physician offices, and drugs and devices.
- •About $2.5T flows through private insurers, including Medicare Advantage and managed Medicaid
- •Administrative cost is one of the biggest gaps versus other countries
- •Remaining spend is about a third hospitals, a third physicians and clinics, a third drugs and devices
- •The thirds framing is more transparent than the older half/third/sixth view
- 16:39 – 26:48
History: From Out-of-Pocket Care to Medicare and Medicaid
Attia asks what healthcare looked like in the 1950s. Sutaria describes the shift from mostly out-of-pocket payment at under 5% of GDP to third-party payment, the Hill-Burton hospital build-out, and the creation of Medicare and Medicaid in 1965.
- •In the 1950s over half of spending was out of pocket; today 85% is covered by a third party
- •Federal share rose from about 12.5% to over 35%
- •Hill-Burton aimed to put a hospital within reach of every American
- •Medicare arose because seniors spent a quarter of their Social Security on care
- •Healthcare has grown about 2% per year faster than GDP, and other developed nations also rose from about 4% to 11–12%
- 26:48 – 31:32
What Medicare and Medicaid Cover
Attia asks Sutaria to define CMS, Medicare and Medicaid. Sutaria explains who qualifies for each, with Medicaid covering about 90 million people and Medicare about 65 million, heading toward 90 million by the early 2030s.
- •Medicare covers everyone at 65 plus some with severe chronic illness such as dialysis patients
- •Medicaid is a safety net for people below state-defined poverty thresholds
- •Medicaid covers about 90 million people, more than Medicare
- •The federal poverty level is low, so the ACA exchanges fill gaps for the under-insured
- 31:32 – 39:10
Why the US Kept Employer-Based Insurance and the Virtuous Cycle of Spending
Attia asks why the US did not roll Medicare out to everyone in the 1960s. Sutaria answers that employer-sponsored insurance was already entrenched and valued for choice. He argues that innovation plus socialized coverage drove consumption, and Attia illustrates with the Riyadh air-conditioning story.
- •Employer-sponsored insurance was entrenched by tax incentives a decade before Medicare
- •Group insurance socialized risk, and employers often paid 100% of premiums
- •Innovation in drugs, devices, and procedures combined with coverage to drive up consumption
- •Attia's Riyadh air-conditioning story illustrates the lack of skin in the game
- 39:10 – 48:21
Insurance as a Discount Card and What the Industry Has Done on Cost
Sutaria argues that insurance was designed for rare, unpredictable events but now mostly covers chronic illness, making it function like a discount card. He explains insurer risk pools and how hard it would be to start an insurer. He also lists what industry has done on costs, such as fewer bed days, more physicians, managed care and Medicare Advantage.
- •Chronic illness drives spending, so insurance is used for predictable needs
- •Insurers' risk differs from car or life insurance, with 5% of people driving roughly half of spend
- •Starting an insurer requires a large risk pool and substantial capital
- •Hospital bed days per thousand fell by half while physicians per thousand roughly doubled
- •Tight managed care controlled costs briefly before a consumer backlash; Medicare Advantage added choice
- 48:21 – 54:31
Managing Costs, Physician Pay, and PPO, HMO and Kaiser Explained
The conversation turns to physician compensation and training debt, then to how plan types work. Sutaria explains PPOs, HMOs, and Kaiser's integrated model, noting that PPO growth reflects the American preference for choice over cost.
- •Real physician compensation has been flat or declining since the 1990s despite US salaries being highest
- •PPOs offer open network choice, while HMOs narrow choice for lower cost
- •PPO enrollment is growing faster than HMO
- •Kaiser is a closed-network integrated model, and Sutaria describes clinicians referring out for rare problems
- 54:31 – 59:49
US vs Canada: Choice, Access, and the Innovation Role
Attia shares his view of the Canadian system as similar in top-tier quality but slower in access. Sutaria says emergency care is fast everywhere and the difference is elective-care wait times from supply constraints. He adds that the US uniquely leads global healthcare innovation.
- •Top surgeons in Canada and the US are comparable, but waits for elective care differ greatly
- •Sutaria describes wait times as a supply-side way of capping demand under universal coverage
- •Nowhere in the developed world is access fully equitable
- •US academic centers and companies drive much of global research and about 75–80% of new drugs
- 59:49 – 1:08:21
Drug Pricing, Price Controls and the Medicare Negotiation Ban
Attia asks what the US gets for effectively subsidizing the rest of the world's drug prices. Sutaria traces rising drug development costs and the 2000 Medicare Modernization Act, which barred HHS from negotiating, and says the Inflation Reduction Act cracked that door open. He notes Medicare already sets prices for doctors and hospitals.
- •Other countries use price controls while US drug prices absorb the pressure
- •The Medicare Modernization Act forbade HHS from negotiating drug prices
- •The Inflation Reduction Act opened limited negotiation
- •Medicare already acts as a monopsonist for doctors and hospitals
- •Debate centers on curbing price growth without deterring innovation
- 1:08:21 – 1:17:42
PBMs, Rebates and Misaligned Incentives
Sutaria explains what pharmacy benefit managers are and how rebates created a complex flow of money. Attia relays a pharma CEO's account of a PBM refusing to list a lower-priced drug and the two discuss me-too drugs and how doctors never see drug costs.
- •PBMs were created as intermediaries to manage formularies and benefits across thousands of drugs
- •Rebates can create incentives for higher-priced products to move through the system
- •Attia relays a pharma CEO's story of being told to triple a price to be listed
- •Physicians prescribing without knowing price differences adds unnecessary cost
- •Other countries restrict access to costlier incremental drugs, while the US favors physician choice
- 1:17:42 – 1:23:16
Sustainability, Debt and an Aging, Shrinking Workforce
Using the national debt as context, the two ask how healthcare could climb toward a third of the economy. Sutaria points to aging peaking around 2032, but the ratio of working-age people to Medicare beneficiaries falls from about two-to-one toward one-to-one, tying immigration to healthcare.
- •Attia cites the deficit and the $35T debt to question whether rising health costs are tenable
- •Sutaria sees a mitigant in the aging peak around 2032 and in modest health-status gains
- •The ratio of 40–65-year-olds to Medicare enrollees is trending from 2:1 toward 1:1
- •Immigration and the workforce are linked to healthcare financing
- 1:23:16 – 1:36:11
Why US Life Expectancy Lags Yet Excels After 70
The two examine why the US trails peers in life expectancy overall but leads after about age 70. Sutaria attributes the early deficit to infant mortality, injuries and homicides, substance abuse, and obesity-related disease, concluding these are largely not insurance problems. Attia then frames quality, cost, access and choice as competing variables.
- •The US is about three years behind peers despite spending the most
- •Between roughly 60 and 75 the US goes from last to first because of the sophistication of its medical system
- •Infant mortality, homicides, injuries, overdoses and obesity drive excess mortality under 65
- •Sutaria says this is not a coverage problem and public health has been ineffective on chronic disease
- •Attia argues choice is a fourth variable that leaves cost unconstrained
- 1:36:11 – 1:47:12
Options for Controlling Drug Costs: Medicare Purchasing at Scale
Attia proposes the null option of doing nothing, then asks what happens to prices if Medicare also becomes a price setter. Sutaria argues against extremes, says purchasing at scale is not un-American, and warns the drug pipeline will push drugs' share of spending higher while the US lacks a national health framework.
- •Sutaria says nobody is proposing to match OECD prices and that doing so in one move would shock the industry
- •He compares Medicare buying at scale to Walmart procurement
- •Orphan drugs and a large biologics pipeline will increase drug spend
- •Other countries have established frameworks for new drugs, but the US has no national health goals
- •Incremental dollars face a tradeoff between the current system and nutrition and activity
- 1:47:12 – 1:55:52
GLP-1 Drugs: Bull Case, Bear Case, and Pricing
Attia raises the rising burden of obesity and diabetes and the GLP-1 bull and bear cases. Sutaria says the drugs are effective, argues the economics favor treating working-age people, notes uncertainty about persistence and spend delay, and expects prices to fall as use broadens.
- •Type 2 diabetes prevalence rose from about 1% to 10–15% since the 1970s
- •Attia calls the bear case a system on the verge of bankruptcy
- •Sutaria says the best economic use is on people who can still work
- •Open questions include whether the drugs delay spend or avoid it, and effects of withdrawal
- •He believes prices are too high and will come back into reasonable parameters
- 1:55:52 – 2:05:49
Cutting Healthcare Spending: Jobs, Administration, AI and Wage Effects
Attia asks whether a 25% reduction in spending is possible. Sutaria says absolute cuts would mean major job losses and that bending the trend toward GDP growth is more realistic. They discuss administrative costs as the price of choice, AI's role in claims, and why the economy has tolerated high spending.
- •A 25% cut would be a severe shock because healthcare is mostly people
- •Sutaria distinguishes absolute reduction from bending the trend to GDP growth
- •AI can cut administrative cost but can also drive denials or over-coding without checks
- •Administration is the price of choice, and other countries hold it in a single government entity
- •Sutaria argues healthcare spending has not yet deterred the economy and may have suppressed wages
- 2:05:49 – 2:11:38
Government Regulation and Moving Care to Lower-Cost Settings
Sutaria says healthcare is over-regulated but credits regulation for quality and safety standards. He says value-based care has mostly not succeeded and that shifting care to lower-cost sites, such as colonoscopies and joint replacements in ambulatory centers, offers more direct savings.
- •Regulation has improved consistency, such as quality standards for sepsis
- •Value-based care efforts have mostly failed, with Medicare Advantage the most successful at scale
- •Moving colonoscopies to outpatient settings increased screening and prevented cancers
- •Joint replacements in ambulatory centers cost about half as much as in hospitals
- 2:11:38 – 2:21:51
Hospital Billing: DRGs, Charges and Medical Debt
Attia asks how a heart surgery is billed. Sutaria explains professional versus technical fees, the DRG bundle, and the difference between cost, price and charge, including why chargemaster prices like the $16 gauze are artificial. He ties this to the uninsured, bad debt and medical bankruptcy.
- •Professional fees go to the surgeon and anesthesiologist, while technical fees are bundled into a hospital DRG
- •Surgeon fees are small relative to the hospital payment
- •Chargemaster prices are the starting point for negotiated rates, and nobody is paid those amounts
- •The uninsured face the full charges, though hospitals often discount heavily
- •Bad debt runs to billions each year
- 2:21:51 – 2:28:07
The ACA, Exchanges and the Individual Mandate
Attia asks why anyone is uninsured today, leading to the ACA's coverage expansion. Sutaria explains Medicaid expansion and the exchanges, the legal challenge to the individual mandate, and why spending rose, since broader coverage raises demand and value-based efforts have not paid off.
- •Uninsured rates fell through Medicaid expansion, strong employment, and the exchanges
- •Attia notes the individual mandate is essential to avoid adverse selection
- •Sutaria calls the ACA effectively a coverage act that increased expenditures
- •Remaining uninsured include undocumented people and those who opt out
- •CMS spent more on innovation models than it saved
- 2:28:07 – 2:36:25
Medicare for All, Cross-Subsidies and Bending the Cost Curve
Attia asks about a credible Medicare-for-everyone proposal. Sutaria says none exists and that coverage is not the missing piece. He explains how commercial insurance cross-subsidizes under-reimbursing government programs, says he is optimistic about aligning inflation with GDP growth, and calls for a ten-year national health objective.
- •A single government plan would effectively be a price control and supply-side intervention
- •Employer-sponsored insurance cross-subsidizes government under-reimbursement
- •Sutaria favors bringing healthcare inflation closer to GDP growth over a 25% cut
- •He sees nutrition and physical activity as key to chronic disease costs
- •A ten-year national health objective is needed, since short-term interests may run counter
- 2:36:25 – 2:45:37
Long-Term Care, Dementia, Technology and Closing Thoughts
Attia notes the US spends less on long-term care and asks about dementia. Sutaria describes neurocognitive decline as a major innovation challenge, with family caregiving carrying hidden economic costs, and sees engineering-based solutions rising. They then discuss AI, with administrative savings first and clinical potential longer term, before closing with personal thanks.
- •US long-term care spending is lower partly because families provide much of the care, at a cost in lost wages
- •The blood-brain barrier limits traditional drug approaches to brain disease
- •Sutaria expects engineering and device-based solutions to grow and calls this a roughly 25-year problem
- •AI's first application is administrative, and the EMR gave an organized foundation but not transformation
- •Attia says the optimistic takeaway is that bending the cost curve toward GDP growth may suffice
